chimeric antigen receptor
Recently Published Documents


TOTAL DOCUMENTS

2522
(FIVE YEARS 1395)

H-INDEX

95
(FIVE YEARS 26)

Neoplasia ◽  
2022 ◽  
Vol 24 (2) ◽  
pp. 98-108
Author(s):  
Hyeon Ho Lee ◽  
Irene Kim ◽  
Un Kyo Kim ◽  
Suk San Choi ◽  
Tae Yang Kim ◽  
...  

2022 ◽  
Vol 16 ◽  
pp. 101309
Author(s):  
Xiao-Hong Chen ◽  
Ruo Chen ◽  
Ming-Yan Shi ◽  
Ruo-Fei Tian ◽  
Hai Zhang ◽  
...  

2022 ◽  
Vol 11 ◽  
Author(s):  
Luyao Wang ◽  
Yurong Chen ◽  
Xinrui Liu ◽  
Ziyi Li ◽  
Xiangpeng Dai

Cancer is one of the main causes of disease-related deaths in the world. Although cancer treatment strategies have been improved in recent years, the survival time of cancer patients is still far from satisfied. Cancer immunotherapy, such as Oncolytic virotherapy, Immune checkpoints inhibition, Chimeric antigen receptor T (CAR-T) cell therapy, Chimeric antigen receptor natural killer (CAR-NK) cell therapy and macrophages genomic modification, has emerged as an effective therapeutic strategy for different kinds of cancer. However, many patients do not respond to the cancer immunotherapy which warrants further investigation to optimize this strategy. The clustered regularly interspaced short palindromic repeats and CRISPR-associated protein 9 (CRISPR/Cas9), as a versatile genome engineering tool, has become popular in the biology research field and it was also applied to optimize tumor immunotherapy. Moreover, CRISPR-based high-throughput screening can be used in the study of immunomodulatory drug resistance mechanism. In this review, we summarized the development as well as the application of CRISPR/Cas9 technology in the cancer immunotherapy and discussed the potential problems that may be caused by this combination.


2022 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Jan Koedam ◽  
Martin Wermke ◽  
Armin Ehninger ◽  
Marc Cartellieri ◽  
Gerhard Ehninger

Author(s):  
Mohadeseh Mirzaee Godarzee ◽  
Bashdar Mahmud Hussen ◽  
Ehsan Razmara ◽  
Benyamin Hakak‐Zargar ◽  
Fatemeh Mohajerani ◽  
...  

2022 ◽  
Author(s):  
Kyle G Daniels ◽  
Shangying Wang ◽  
Milos S Simic ◽  
Hersh K Bhargava ◽  
Sara Capponi ◽  
...  

Chimeric antigen receptor (CAR) costimulatory domains steer the phenotypic output of therapeutic T cells. In most cases these domains are derived from native immune receptors, composed of signaling motif combinations selected by evolution. To explore if non-natural combinations of signaling motifs could drive novel cell fates of interest, we constructed a library of CARs containing ~2,300 synthetic costimulatory domains, built from combinations of 13 peptide signaling motifs. The library produced CARs driving diverse fate outputs, which were sensitive motif combinations and configurations. Neural networks trained to decode the combinatorial grammar of CAR signaling motifs allowed extraction of key design rules. For example, the non-native combination of TRAF- and PLCg1-binding motifs was found to simultaneously enhance cytotoxicity and stemness, a clinically desirable phenotype associated with effective and durable tumor killing. The neural network accurately predicts that addition of PLCg1-binding motifs improves this phenotype when combined with TRAF-binding motifs, but not when combined with other immune signaling motifs (e.g. PI3K- or Grb2- binding motifs). This work shows how libraries built from the minimal building blocks of signaling, combined with machine learning, can efficiently guide engineering of receptors with desired phenotypes.


Sign in / Sign up

Export Citation Format

Share Document